Oct 14th Geron initiates randomized Phase 2 clinical trial of imetelstat in breast cancer. Enrollment of the first patient using a telomerase inhibitor drug GRN163L. The results will be known the end of 2012.
The high for the was on Wed. Oct 12th of $2.38, the low of $2.18 was on Mon. Oct 10th. The avg. volume is going down. The one year update on Oct 16th, on there Phase 1 GRNOPC1 looks like no great news. I'm basing this on no increase in volume or price. I hope I'm wrong.
Good luck in this rigged casino,
No comments:
Post a Comment